Reduction in Multiple Cardiometabolic Risk Factors With Combined Olanzapine/Samidorphan Compared With Olanzapine: Post Hoc Analyses From a 24-Week Phase 3 Study.

Additionally, among patients without metabolic syndrome at baseline, a numerically smaller proportion of patients treated with OLZ/SAM went on to meet any individual component criterion of metabolic syndrome compared with those treated with olanzapine, although the differences did not reach statistical significance (NNT range: 20–23).

also in 111,027 other papers